The phrase 'in future submissions' is correct and usable in written English.
You can use it when referring to something that will be submitted in the future. For example: "Please ensure that you meet the deadline for all future submissions."
However, the aim of this checklist is not to score submissions by counting the number of "yes" answers, but to avoid methodological and technical errors in future submissions by using this instrument when compiling pharmaceutical reimbursement dossiers.
Of the current names utilised, we suggest that the naming system employed by Goto et al. [ 1] is used in future submissions, since it is derived from the most detailed functional analysis and suitably describes the evolutionary relationships of different orthologues and paralogues.
For one product, Belgium Health Authority asked this test to be included in future submission for a product.
The purpose of this research study was to identify common issues and concerns identified by the ERGs in their analyses of MS and to use these as a basis to provide feedback to manufacturers to assist them in future submission development as well as recommendations to the ERGs and NICE.
If users knew that their submission in one group could be flagged for moderation, resulting in moderation of future submissions across all groups of which they were a member, they figured 'why bother?'.
These changes would allow authors to feel more involved in the process and therefore encourage future submissions.
In any case, the thematic issue will remain open for future submissions associated with InChI as the technology expands in capability and applications.
Regarding a more comprehensive discussion of related work and comparisons of rebound responses: We certainly intend on following this advice in future journal submissions.
Colibrí had entered over 1,300 of their reports into the system until a change in NamUS policy restricted the nonprofit from publishing future submissions.
This factor is critical for the success of renewals and future submissions.
The cardiac troponin submission is the first literature-based biomarker application to be reviewed by the FDA and insights gained from this experience may aid future submissions and help streamline the characterization and qualification of future biomarkers.
